ReviewAbdominal radiology (New York)2020
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Review in Abdominal radiology (New York), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.European radiology · 2021Pooled it
- Malpractice claims for pancreatic cancer in Norway: claim-rates, injury domains, claim outcomes and indemnity compensation.Acta oncologica (Stockholm, Sweden) · 2026Article
- CT habitat radiomics and topological data analysis based on interpretable machine learning for prediction of pancreatic ductal adenocarcinoma pathological grading.BMC medical imaging · 2025Article
- Total non-division technique of pancreaticoduodenectomy: A strategic integration of superior mesenteric artery-first approach and total mesopancreas excision.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy.BMC cancer · 2024Article
- Inter-reader agreement of pancreatic adenocarcinoma resectability assessment with photon counting versus energy integrating detector CT.Abdominal radiology (New York) · 2024Article
- Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB.ESMO gastrointestinal oncology · 2024Article
- Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma.World journal of gastrointestinal oncology · 2024Article
- Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data.Clinical and translational radiation oncology · 2024Article
- Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT,Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer.Cancer medicine · 2023Article
- Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Treatment of pancreatic cancer in 2022.Cambridge prisms. Precision medicine · 2023Review
- Article
- Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution.World journal of surgical oncology · 2022Article
- MicroRNA‑190b expression predicts a good prognosis and attenuates the malignant progression of pancreatic cancer by targeting MEF2C and TCF4.Oncology reports · 2022Article
- Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine.Diagnostics (Basel, Switzerland) · 2021Review
- Use of stents in patients undergoing chemotherapy for borderline resectable pancreatic cancer-causing biliary obstruction while awaiting surgery: A cost-effectiveness analysis.Endoscopy international open · 2021Article
- Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
- The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine.GE Portuguese journal of gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal malignancy with a poor 5-year survival rate. Accurate staging of PDAC is an important initial step in the development of a stage-specific treatment plan. Different staging systems/consensus statements convened by different societies and academic practices are currently used. The most recent version of the American Joint Committee on Cancer (AJCC) tumor/node/metastases (TNM) staging system for PDAC has shifted its focus from guiding management to assessing prognosis. In order to preoperatively define the resectability of PDAC and to guide management, additional classification systems have been developed. The National Comprehensive Cancer Network (NCCN) guidelines, one of the most commonly used systems, provide recommendations on the management and the determination of resectability for PDAC. The NCCN divides PDAC into three categories of resectability based on tumor-vessel relationship: 'resectable,' 'borderline resectable,' and 'unresectable'. Among these, the borderline disease category is of special interest given its evolution over time and the resulting variations in the definition and the associated recommendations for management between different societies. It is important to be familiar with the evolving criteria, and treatment and follow-up recommendations for PDAC. In this article, the most current AJCC staging (8th edition), NCCN guidelines (version 2.2019-April 9, 2019), and challenges and controversies in borderline resectable PDAC are reviewed.
Indexed as
Identifiers
31748823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.